Aktis Oncology, Inc. (AKTS) fair value analysis
Nasdaq · Updated 2026-10-19
AKTS price how computed
Valuation status
No fair-value estimate yetAKTS has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for AKTS yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $15.06
- Sector
- Healthcare
- 12-month range
- $15.06–$30.89
- Market cap
- $809M
- From 52-week high
- -51.2%
- Shares outstanding
- 53.7M
- Rank in Healthcare by quality score
- #174 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Aktis Oncology, Inc. is a biopharmaceutical company focused on developing novel therapies for cancer treatment. The company operates in the United States and is engaged in the discovery and development of oncology drugs targeting various cancer types.
AKTS currently ranks #174 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $809M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $10.1M
- Net margin
- -727.0%
- EPS (TTM)
- $-17.16
- Gross margin
- 74.0%
- Debt / equity
- 0.02
- Revenue growth (3-yr avg)
- -19.8%
- Shares outstanding
- 53.7M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 13 · oversold
Earnings how computed
- Next earnings report
- 2026-11-12
- Last 8 quarters vs consensus
- 2 beat, 5 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▼ miss (-15.2%)
2025-12 ▲ beat (+75.3%)
2025-09 ▼ miss
2024-09 ▲ beat (+50.0%)
2024-03 ▼ miss (-16.7%)
2023-12 ▼ miss (-5.6%)
2023-09 ▼ miss (-50.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 0 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $35.4
- Target vs last price
- +135.1%
What our data shows for AKTS
- Shares are trading in the lower third of their 12-month price range of $15.06–$30.89.
- The 14-day relative strength index sits at an oversold 13.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- AKTS's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the AKTS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is AKTS stock undervalued?
TickrTrends has no fair-value estimate for AKTS yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is AKTS's TickrTrends verdict?
AKTS is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does AKTS compare to other Healthcare stocks?
AKTS ranks #174 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is AKTS overbought or oversold?
AKTS's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does AKTS report earnings next?
AKTS's next earnings report is scheduled for 2026-11-12, per the published earnings calendar.
Does AKTS usually beat earnings estimates?
Over its last 8 reported quarters AKTS beat the consensus estimate 2 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AKTS?
Of 10 analysts covering AKTS, 10 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $35.4 (+135.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.